InMode Newsroom

InMode Faces Macroeconomic Challenges and Manufacturing Disruptions, Leading to Hold Rating

TipRanksJan 10 08:07 ET

Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $26

Moomoo NewsJan 10 05:34 ET

InMode Is Maintained at Overweight by Barclays

Dow JonesJan 9 06:49 ET

InMode Price Target Cut to $26.00/Share From $27.00 by Barclays

Dow JonesJan 9 06:49 ET

InMode Analyst Ratings

BenzingaJan 9 06:39 ET

Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $26

Moomoo NewsJan 8 18:32 ET

Needham Maintains InMode(INMD.US) With Hold Rating

Moomoo NewsJan 8 10:33 ET

Needham Remains a Hold on InMode (INMD)

TipRanksJan 8 09:38 ET

BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsJan 8 09:31 ET

Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)

TipRanksJan 8 09:13 ET

UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating

MT NewswiresNov 1, 2024 10:00 ET

InMode Analyst Ratings

BenzingaOct 31, 2024 06:05 ET

Needham Maintains InMode(INMD.US) With Hold Rating

Moomoo NewsOct 30, 2024 15:33 ET

InMode Analyst Ratings

BenzingaOct 17, 2024 06:07 ET

BTIG Initiates InMode(INMD.US) With Buy Rating, Announces Target Price $25

Moomoo NewsOct 16, 2024 16:33 ET

InMode's Strategic Growth Potential and Market Positioning: A Buy Recommendation by Marie Thibault

TipRanksOct 16, 2024 16:27 ET

InMode Initiated With a Buy at BTIG

TipRanksOct 16, 2024 16:20 ET

InMode Is Maintained at Overweight by Barclays

Dow JonesOct 14, 2024 10:32 ET

Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $27

Moomoo NewsOct 14, 2024 04:32 ET

Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $27

Moomoo NewsOct 12, 2024 09:31 ET